TY - JOUR AU - Chang, Kuang-Leei AU - Lee, Ming-Yung AU - Chao, Wan-Ru AU - Han, Chih-Ping PY - 2016 DA - 2016/12/28 TI - The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma JO - Human Genomics SP - 40 VL - 10 IS - 1 AB - Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I). SN - 1479-7364 UR - https://doi.org/10.1186/s40246-016-0096-9 DO - 10.1186/s40246-016-0096-9 ID - Chang2016 ER -